Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel Y5 receptor ligands in development at Ortho-McNeil for obesity and other disorders

Nov. 24, 1999

Tanox patents G-CSF receptor agonists, including MAbs, and their use

Nov. 23, 1999

BMS seeks approval in U.S. for Glucophage XR tablets

Nov. 22, 1999

Pfizer discusses preclinical PK of new MTP inhibitor, CP-346086, at 1999 AAPS meeting

Nov. 19, 1999

AAPS news: Pfizer finds CP-467688 superior to CP-319340 in terms of pharmacokinetics

Nov. 19, 1999

Erythropoietin receptor-modulating agents discovered at Ortho-McNeil

Nov. 19, 1999

Detailed pharmacokinetics, pharmacodynamics and toxicokinetics reported for CI-1027

Nov. 18, 1999

Pharmacokinetics of CP-331684 investigated in animal species

Nov. 18, 1999

AAPS presentation for new beta3-adrenoceptor agonist: preclinical PK/PD of GW-0604

Nov. 18, 1999

FDA requests confirmatory trial of Aldurazyme prior to BLA filing

Nov. 18, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...